These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21830280)

  • 21. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study.
    Vermeire S; Noman M; Van Assche G; Baert F; Van Steen K; Esters N; Joossens S; Bossuyt X; Rutgeerts P
    Gastroenterology; 2003 Jul; 125(1):32-9. PubMed ID: 12851868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Infliximab infusion reactions: desensitizing ourselves to the danger.
    Persley KM
    Inflamm Bowel Dis; 2004 Jan; 10(1):62-3. PubMed ID: 15058530
    [No Abstract]   [Full Text] [Related]  

  • 23. [Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?].
    Heidemann J; Kucharzik T
    Z Gastroenterol; 2005 Jul; 43(7):689-90. PubMed ID: 16001352
    [No Abstract]   [Full Text] [Related]  

  • 24. [Anti-TNF antibodies in the treatment of inflammatory intestinal stenoses in Crohn's disease].
    Holtmann M; Wanitschke R; Helisch A; Bartenstein P; Galle PR; Neurath M
    Z Gastroenterol; 2003 Jan; 41(1):11-7. PubMed ID: 12541166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection.
    del Valle García-Sánchez M; Gómez-Camacho F; Poyato-González A; Iglesias-Flores EM; de Dios-Vega JF; Sancho-Zapatero R
    Inflamm Bowel Dis; 2004 Sep; 10(5):701-2. PubMed ID: 15472541
    [No Abstract]   [Full Text] [Related]  

  • 26. [Anti-TNF (infliximab) treatment in Crohn disease: safety profile].
    Carroccio A; Di Prima L; Pirrone G; Ambrosiano G; Noto D; Cefalù AB
    Recenti Prog Med; 2006 Feb; 97(2):108-12; quiz 122. PubMed ID: 16671277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cutaneous nevi pigmentosus during infliximab therapy in a patient with Crohn's disease: fallacy or coincidence?
    Katsanos KH; Christodoulou DK; Zioga A; Tsianos EV
    Inflamm Bowel Dis; 2003 Jul; 9(4):279. PubMed ID: 12902853
    [No Abstract]   [Full Text] [Related]  

  • 28. Infliximab (Remicade): the magic bullet for Crohn's disease?
    D'Haens G
    Dig Liver Dis; 2000 Nov; 32(8):653-6. PubMed ID: 11142571
    [No Abstract]   [Full Text] [Related]  

  • 29. Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease.
    Thomas CW; Weinshenker BG; Sandborn WJ
    Inflamm Bowel Dis; 2004 Jan; 10(1):28-31. PubMed ID: 15058523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-tumour necrosis factor therapy in Crohn's disease: where are we now?
    van Deventer SJ
    Gut; 2002 Sep; 51(3):362-3. PubMed ID: 12171957
    [No Abstract]   [Full Text] [Related]  

  • 31. [Meningitis due to Listeria monocytogenes as a complication of infliximab therapy].
    Joosten AA; van Olffen GH; Hageman G
    Ned Tijdschr Geneeskd; 2003 Jul; 147(30):1470-2. PubMed ID: 12908351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated serum IgE prior to acute severe infusion reaction during infliximab maintenance therapy in a Crohn's disease patient.
    Kato S; Kobayashi T; Kani K; Takabayashi H; Yamamoto R; Yakabi K
    Inflamm Bowel Dis; 2011 Dec; 17(12):E156-7. PubMed ID: 21898702
    [No Abstract]   [Full Text] [Related]  

  • 33. Fatal staphylococcal sepsis in Crohn's disease after infliximab.
    Herrlinger KR; Borutta A; Meinhardt G; Stange EF; Fellermann K
    Inflamm Bowel Dis; 2004 Sep; 10(5):655-6. PubMed ID: 15472530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sight-threatening keratopathy complicating anti-TNF therapy in Crohn's disease: a case report.
    Fasci-Spurio F; Thompson A; Madill S; Koay P; Mansfield D; Satsangi J
    Inflamm Bowel Dis; 2014 Jan; 20(1):E2-3. PubMed ID: 24280880
    [No Abstract]   [Full Text] [Related]  

  • 35. Infliximab: how to use it in pediatric Crohn's disease.
    Ruemmele FM
    J Pediatr Gastroenterol Nutr; 2004 Jul; 39(1):12-4. PubMed ID: 15187774
    [No Abstract]   [Full Text] [Related]  

  • 36. In vivo single-photon emission computed tomography imaging of apoptosis in Crohn's disease and anti-tumour necrosis factor therapy.
    Watson AJ
    Gut; 2007 Apr; 56(4):461-3. PubMed ID: 17369380
    [No Abstract]   [Full Text] [Related]  

  • 37. [Indications and results of infliximab in Crohn's disease].
    Karoui S; Boubaker J; Filali A
    Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psoriasis and psoriatic arthritis induced in a patient treated with infliximab for Crohn's disease.
    Tichy M; Tichy M; Kopova R; Sternbersky J; Ditrichova D
    J Dermatolog Treat; 2012 Jun; 23(3):208-11. PubMed ID: 21254868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
    Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unusual presentation of tuberculosis after infliximab therapy.
    Magro F; Pereira P; Veloso FT; Carneiro F
    Inflamm Bowel Dis; 2005 Jan; 11(1):82-4. PubMed ID: 15674123
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.